Direct supply, batch-certified purity, and custom scale-up configurations for frontline therapeutic programs.
Unlocking global biopharmaceutical procurement competitiveness through integrated supply infrastructure and advanced SPPS engineering.
Unlike Western contract synthesis facilities that depend on offshore supply chains for building blocks, our Hangzhou synthesis base is directly integrated with indigenous Chinese manufacturing of Fmoc/Boc protected amino acids, specialized coupling reagents (HATU, HBTU, PyBOP), and high-substitution Wang/CTC resins.
Thinheal operates industrial synthesis lines featuring automated 500L to 3000L solid-phase reaction vessels, coupled with dynamic axial compression preparative HPLC columns (DAC up to 1000mm diameter). This physical layout delivers unprecedented economies of scale.
Operating under stringent adherence to ICH Q7 guidelines, our facility maintains a mature Quality Management System (QMS) supporting DMF generation, continuous process verification, and international regulatory readiness.
Quantifiable metrics demonstrating our manufacturing readiness and analytical consistency.
Bridging peptide chemistry with modern drug delivery systems across high-incidence chronic diseases.
The global surge in obesity, type 2 diabetes mellitus (T2D), and metabolic dysfunction-associated steatohepatitis (MASH/NASH) requires long-chain, lipophilic peptides. We manufacture long-acting GLP-1 analogues, dual GLP-1/GCG agonists (Mazdutide), and dual GLP-1/GIP agonists.
Semaglutide Mazdutide Tirzepatide Intermediates OrforglipronOur chemical strategies resolve aggregation challenges in hydrophobic sequences via pseudoproline dipeptides and optimized cleavage-cocktail protocols.
Targeted solutions for orphan diseases and critical gastrointestinal deficiencies, specifically short bowel syndrome (SBS) requiring GLP-2 receptor agonists (Teduglutide) and selective enteric secretagogues.
Teduglutide (GLP-2) Linaclotide PlecanatideEquipped with precision disulfide loop formation technologies (single and multiple bridge cyclization via orthogonal protective groups like Acm and Trt) ensuring target tertiary conformation.
Peptide therapeutics addressing central nervous system pathologies, stress-induced anxiety, and pituitary regulation require precise formulation and zero-endotoxin manufacturing.
Semax Heptapeptide Selank Regulatory Peptide Vasopressin (ADH) Tesamorelin (GHRH)Lyophilization protocols engineered to maintain amorphous powder stability, low moisture content (<3.0%), and strictly controlled bioburden for sterile injectables.
Supplying critical gonadotropin-releasing hormone (GnRH) agonists such as Triptorelin and Leuprolide engineered specifically for compatibility with PLGA/PLA microsphere sustained-release delivery systems.
Triptorelin Acetate/Pamoate Goserelin BuserelinTight control over micro-particle surface charge, specific counter-ion balancing, and residual TFA substitution by acetate to prevent polymer matrix catalytic degradation.
Industrial batches of peptides driving tissue repair, actin-sequestering, and cellular migration pathways for surgical recovery, wound management, and immune homeostasis.
Thymosin β4 (TB-500) Thymalin Polypeptide BPC-157High-yield SPPS synthesis guarantees consistent peptide content calculation and reproducible bioactivity across successive commercial campaigns.
Supplying signal peptides, neurotransmitter-inhibiting oligopeptides, and copper-binding complexes to medical-grade aesthetics brands requiring high lot-to-lot traceability.
Palmitoyl Oligopeptides GHK-Cu Complex Acetyl Hexapeptide-8Lipophilic modification technologies (palmitoylation, myristoylation) designed to enhance dermal penetration without degrading primary purity.
A technical guide for qualified person (QP) teams, procurement officers, and regulatory specialists qualifying peptide suppliers.
Global regulatory bodies (US FDA CDER, EMA CHMP, WHO) demand exhaustive clarity regarding synthetic peptide impurity profiles. A simple percentage value on a Certificate of Analysis (CoA) is no longer sufficient.
Thinheal bridges raw chemistry with registrational compliance, reducing regulatory lag times for global sponsors moving through Phase I, II, III clinical trials to commercial dossier clearance.
Direct supply contracts, multi-kilo lot availability, and customized salt formulations ready for quotation.
Critical scientific, commercial, and regulatory guidance on therapeutic peptide manufacturing in China.
Our capacity is anchored by industrial-scale automated synthesis reactors ranging from 500L to 3000L. Chiral integrity is preserved through automated parameter tracking during the coupling phase, using low-racemization activating cocktails (such as Oxyma/DIC instead of HBTU/DIPEA where appropriate), precisely calibrated temperatures below threshold racemization limits, and high-frequency in-line UV deprotection monitoring. Every commercial batch undergoes stereochemical purity confirmation using Chiral Amino Acid Analysis (AAA) following acid hydrolysis.
This is the most common procurement pitfall. HPLC Purity represents the area percentage of the main peptide peak relative to related peptide substances detected at 214nm or 220nm. Net Peptide Content reflects the actual percentage of peptide molecule weight relative to the gross weight of the powder, which inherently contains counter-ions (such as acetate or trifluoroacetate) and residual hygroscopic water. Thinheal provides quantitative Net Peptide Content determined via quantitative amino acid analysis or nitrogen elemental analysis to ensure precise therapeutic dosing during drug product formulation.
Yes. Standard SPPS cleavage uses Trifluoroacetic Acid (TFA), leaving residual TFA anions bound to basic amino acid residues (Lys, Arg, His) or the free N-terminus. For injectable therapeutic peptides, residual TFA is tightly restricted due to cellular toxicity. Thinheal utilizes automated preparative ion-exchange chromatography systems using volatile buffer wash cycles (such as ammonium acetate or dilute acetic acid) to exchange TFA for pharmaceutical-grade acetate, ensuring residual TFA levels remain below <0.1% or <0.05% depending on target specifications.
Every commercial batch is accompanied by an audit-ready Certificate of Analysis (CoA) containing:
Peptide APIs are highly susceptible to moisture-induced degradation and deamidation. We lyophilize final materials in Class A/C cleanroom environments to minimize residual moisture (<3.0%). Bulk powders are packed in medical-grade PTFE-lined, nitrogen-purged double polyethylene bags within sealed aluminum canisters. For intercontinental transit from our Hangzhou hub to the Americas, Europe, and Asia, temperature-controlled shipments use validated VIP (Vacuum Insulated Panel) dry ice or chilled phase-change shippers with real-time USB/GPS temperature dataloggers.
Our CDMO platform provides full-lifecycle support: computational route design, custom synthesis of unnatural amino acids, synthesis of fatty-acid conjugated peptides (such as C18/C20 diacid mono-PEG lipid chains for long-acting GLP-1 analogues), head-to-tail or side-chain cyclization, stapled peptide synthesis, and pilot process scale-up. We generate complete CMC dossier packages, perform analytical method validation, and support sponsors through IND application milestones up to commercial validation runs.
Partner with Hangzhou Thinheal Pharma-Tech Co., Ltd. for reproducible peptide purity, verified batch continuity, and global regulatory expertise. Contact our specialized export desks for rapid quotation.
Thin